Article | May 7, 2024

Viral Vector Producer Cell Lines: Learning From mAbs

Source: Cytiva

Gene therapy has made significant progress in recent years, with viral vector-based gene delivery being the primary method. However, the current production methods for adeno-associated virus (AAV) vectors, the most commonly used in gene therapy, are insufficient to meet the demand for therapies. To improve viral vector processing, lessons from the production of monoclonal antibodies (mAbs) can be applied. Key areas of focus include cell line development, cell culture process development, vector design, clone selection, media and process optimization, and quality control. Learn how applying bioprocessing knowledge can accelerate the development of viral vector cell lines and improve efficiency in gene therapy manufacturing.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.

Subscribe to Biosimilar Development X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Biosimilar Development